Document is current
Any future updates will be listed below
-
Authors
Bewersdorf, Jan Philipp https://orcid.org/0000-0003-3352-0902
Mina, Alain
Stahl, Maximilian
Zeidan, Amer M. https://orcid.org/0000-0001-7017-8160
- License Information
-
More Information
Article History
Accepted: 10 March 2026
First Online: 14 April 2026
Competing interests
: M.S. has acted as a consultant and/or adviser of Boston Consulting, BMS, Dedham Group, GLG, GSK, Kura, Kymera, Novartis, Rigel, Sierra Oncology, Sobi and Syndax; has participated in CME activity for Clinical Care Options, Curis Oncology, Haymarket Media and Novartis; and is a member of the Medical Safety Monitoring Board of Keros Pharmaceuticals. A.M.Z. has acted as a consultant and/or adviser of AbbVie, Akesobio, Agios, Amgen, Astellas, BioCryst, Beigene, Boehringer-Ingelheim, Celgene/BMS, Chiesi/Cornerstone Biopharma, Daiichi Sankyo, Dr Reddy, Epizyme, Faron, Fibrogen, GSK, Glycomimetics, Genentech, Gilead, Geron, Janssen, Jasper, Karyopharm, Kyowa Kirin, Keros, Kura, Novartis, Notable, Orum, Otsuka, Pfizer, Regeneron, Rigel, Seattle Genetics, Shattuck Labs, Schrodinger, Syros, Syndax, Servier, Takeda, Treadwell, Taiho, Vincerx and Zentalis. J.P.B. and A.M. declare no competing interests.
